Nabi Biopharmaceuticals Presents Data Showing Patients Treated with Altastaph Were Relieved of Fever and Bacteremia Sooner than the Placebo Group


ROCKVILLE, Md. -- Nabi Biopharmaceuticals announced today, for the first time, data showing that patients treated with Altastaph [Staphylococcus aureus Immune Globulin Intravenous (Human)] had a shorter duration of bacteremia and fever vs. the placebo group.  As previously reported, the treated group also left the hospital sooner.  Altastaph is Nabi Biopharmaceuticals' investigational human antibody-based product in development to treat adult in-hospital patients with persistent S. aureus bacteremia.

Mark E. Rupp, MD, from the University of Nebraska Medical Center, presented the full Phase I/II results at the 43rd Infectious Diseases Society of America (IDSA) annual meeting in San Francisco.

"Infection due to Staphylococcus aureus is a significant medical problem that is, unfortunately, increasingly observed," stated Rupp. "The growing prevalence of antibiotic-resistance in staphylococci reinforces the need for new antibiotics and innovative measures, such as Altastaph. This Phase I/II study showed that Altastaph was generally well tolerated, similar to other IVIG products.  Patients treated with Altastaph had high levels of antibodies, which result in the killing of bacteria.  Additional studies are warranted to further define the efficacy of Altastaph, a promising therapeutic agent."

Rupp's presentation focused on the results of the Altastaph U.S. Phase I/II clinical trial in treating adult in-hospital patients with persistent S. aureus bacteremia.  In this study there was a 36 percent reduction in median time from administration of the study drug to hospital discharge in the Altastaph-treated patients as compared to the placebo-treated patients (nine days in the Altastaph group vs. 14 days in the placebo group).  This

substantial reduction in the length of hospital stays for the Altastaph-treated group indicates that S. aureus antibodies provided by Altastaph could be associated with considerable medical as well as health economic benefit in the treatment of persistent S. aureus infections.

The study results also showed a shorter duration of bacteremia (one day in the Altastaph group vs. two days in the placebo group) and fever (two days in the Altastaph group vs. seven days in the placebo group).

Source: Nabi Biopharmaceuticals



Related Videos
Picture at AORN’s International Surgical Conference & Expo 2024
Rare Disease Month: An Infection Control Today® and Contagion® collaboration.
Infection Control Today Topic of the Month: Mental Health
Lucy S. Witt, MD, investigates hospital bed's role in C difficile transmission, emphasizing room interactions and infection prevention
Shelley Summerlin-Long, MPH, MSW, BSN, RN, senior quality improvement leader, infection prevention, UNC Medical Center, Chapel Hill, North Carolina
An eye instrument holding an intraocular lens for cataract surgery. How to clean and sterilize it appropriately?   (Adobe Stock 417326809By Mohammed)
Christopher Reid, PhD  (Photo courtesy of Christopher Reid, PhD)
Paper with words antimicrobial resistance (AMR) and glasses.   (Adobe Stock 126570978 by Vitalii Vodolazskyi)
Association for the Health Care Environment (Logo used with permission)
Related Content